tiprankstipranks
Trending News
More News >
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
Advertisement

Mainz Biomed B.V. (MYNZ) AI Stock Analysis

Compare
354 Followers

Top Page

MYNZ

Mainz Biomed B.V.

(NASDAQ:MYNZ)

Rating:55Neutral
Price Target:
$2.00
▼(-1.96%Downside)
The overall stock score of 55 reflects significant financial challenges faced by Mainz Biomed B.V., including negative profitability and high leverage. Technical analysis suggests some bullish momentum, but the lack of valuation data and below average long-term price trends highlight substantial risks.
Positive Factors
Market Opportunity
Mainz Biomed's Next-Generation Test has transformative potential in the $4B CRC screening segment in the US by enabling accurate detection of precancerous AAs with a decentralized commercial strategy to accelerate adoption and reduce commercial expenses.
Product Performance
The assay combined with a proprietary algorithm achieved compelling results of 95% sensitivity and 98% specificity for the detection of pancreatic cancer.
Strategic Partnerships
An agreement with Quest Diagnostics has been signed for the ReconAAsense study with an option for commercialization.
Negative Factors
Clinical Study Risks
The feasibility study seeks to evaluate the panel and machine learning algorithm in a clinical sample set to determine sensitivity, specificity, and consistency, posing potential risks if results do not meet expectations.
Market Competition
Existing tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting competitive pressure on Mainz Biomed to capture market share.

Mainz Biomed B.V. (MYNZ) vs. SPDR S&P 500 ETF (SPY)

Mainz Biomed B.V. Business Overview & Revenue Model

Company DescriptionMainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
How the Company Makes MoneyMainz Biomed B.V. generates revenue primarily through the sale of its diagnostic tests, particularly its proprietary colorectal cancer screening test. The company partners with healthcare providers, laboratories, and insurance companies to distribute and administer these tests to patients. Revenue is derived from test sales, partnerships with diagnostic labs that process the tests, and potentially through licensing agreements for their technology. Additionally, collaborations with research institutions and participation in clinical studies may provide supplementary income streams or development funding.

Mainz Biomed B.V. Financial Statement Overview

Summary
Mainz Biomed B.V. faces significant financial challenges with fluctuating revenues, substantial EBIT and net losses, high leverage, and negative operating cash flow. Some improvements in equity and free cash flows are noted, but overall negative profitability and reliance on external funding pose risks.
Income Statement
45
Neutral
Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.
Balance Sheet
40
Negative
The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.
Cash Flow
50
Neutral
Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue893.99K895.48K529.88K577.35K493.56K
Gross Profit574.88K509.66K182.15K177.62K123.08K
EBITDA-19.56M-25.01M-25.72M-11.28M-257.64K
Net Income-21.65M-26.30M-26.45M-12.07M-886.18K
Balance Sheet
Total Assets13.24M15.41M20.24M10.04M673.27K
Cash, Cash Equivalents and Short-Term Investments6.24M7.07M17.14M8.73M122.57K
Total Debt3.27M7.42M3.23M2.58M2.98M
Total Liabilities7.19M12.16M6.14M3.68M3.41M
Stockholders Equity6.05M3.25M14.10M6.36M-2.74M
Cash Flow
Free Cash Flow-17.34M-23.84M-15.43M-3.24M-478.42K
Operating Cash Flow-17.09M-21.94M-14.77M-3.22M-468.74K
Investing Cash Flow-198.82K-1.90M-658.48K1.20M-9.69K
Financing Cash Flow16.60M14.23M23.94M10.61M396.68K

Mainz Biomed B.V. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.04
Price Trends
50DMA
1.86
Positive
100DMA
2.77
Negative
200DMA
5.12
Negative
Market Momentum
MACD
0.06
Negative
RSI
57.09
Neutral
STOCH
66.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Neutral. The current price of 2.04 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.86, and below the 200-day MA of 5.12, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 57.09 is Neutral, neither overbought nor oversold. The STOCH value of 66.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYNZ.

Mainz Biomed B.V. Risk Analysis

Mainz Biomed B.V. disclosed 40 risk factors in its most recent earnings report. Mainz Biomed B.V. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Mainz Biomed B.V. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$21.49M-25.29%26.67%44.02%
61
Neutral
$13.13M-126.34%3.87%91.76%
55
Neutral
$7.59M-809.29%
52
Neutral
$7.61B0.11-63.03%2.07%16.35%0.29%
50
Neutral
$9.88M-290.85%78.40%22.41%
43
Neutral
$12.62M77.20%-4.02%-6.60%
41
Neutral
$11.64M-127.82%-24.04%84.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MYNZ
Mainz Biomed B.V.
2.04
-11.96
-85.43%
TRIB
Trinity Biotech
0.67
-2.09
-75.72%
PRPO
Precipio
14.70
9.44
179.47%
BNGO
BioNano Genomics
3.38
-34.59
-91.10%
INBS
Intelligent Bio Solutions
1.61
0.20
14.18%
BIAF
bioAffinity Technologies, Inc.
0.33
-2.30
-87.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025